Fig. 5: Therapeutic efficacy of 3C-LNPs in an orthotopic HCC model.
From: Gene Therapy with Enterovirus 3 C Protease: A Promising Strategy for Various Solid Tumors
a Timeline of tumor implantation and treatment schedule in the orthotopic (HCC) model. Mice were intravenously injected with PBS or 3C-LNPs (0.4 mg/kg) once every 7 days for a total of 3 doses. b and c Bioluminescence images of luciferase-expressing Huh7-luc tumors after 1, 2, 3, 4 and 5 weeks of treatment (n = 6 mice/group). The data are presented as the means ± SEMs. Statistical differences were assessed using Mixed-effects with the Bonferroni multiple comparisons test. ****P < 0.0001. d Survival curve of the Huh7-luc orthotopic mouse model. Survival analysis was assessed using the log-rank (Mantel–Cox) test. ***P < 0.001. e Changes in the body weights of the tumor-bearing mice in different groups (n = 6 mice/group). f Representative H&E staining of tumor tissues from 6 tumor-bearing mice/group. Scale bar: 1000 μm. g Schematic showing the timeline of the tumor vascular microcirculation monitoring test. The tumor-bearing mice were treated with 3C-LNPs (0.4 mg/kg) and PBS. h Representative images of the functional vasculature of tumors from mice administered 3C-LNPs or PBS (n = 3 mice/group). Scale bar: 1 mm. The data are presented as the means ± SEMs. Statistical differences were assessed using a two-tailed unpaired t-test. **P < 0.01, ***P < 0.001. Source data are provided as a Source Data file.
